Patient Reported Adverse Psychosocial Outcomes and Identification of Predictive Factors in Those with Lymphoma or Chronic Lymphocytic Leukemia - An analysis of the Lymphoma Coalition's 2024 Global Patient Survey
Author(s)
Steve Kalloger1, Amanada Watson, BS2, Shawn Sajkowski, BS2, Lorna Warwick, BA2.
1Las Vegas, NV, USA, 2Lymphoma Coalition, Mississauga, ON, Canada.
1Las Vegas, NV, USA, 2Lymphoma Coalition, Mississauga, ON, Canada.
Presentation Documents
OBJECTIVES: Adverse psychosocial outcomes (APSO’s) are an under-reported phenomenon amongst patients during the cancer journey. The diversity of APSO’s extends well beyond anxiety and depression which are commonly captured in many patient reported outcome measures (PROM’s). In this study, we examined the prevalence of 19 different APSO’s experienced by patients with lymphoma or chronic lymphocytic leukemia (CLL) and explored associations with demographics and various experiential aspects of the cancer journey to provide evidence for the refinement of future PROM instruments.
METHODS: A cross-sectional survey was employed to gather patient reported-outcomes (PRO) from a global sample of patients with lymphoma or CLL in early 2024. Age, biological sex, relapse status, time since last treatment, and time since diagnosis were used as predictors to model the prevalence of 19 APSO’s utilizing nominal logistic regression.
RESULTS: The sample contained 6073 patient responses from 67 countries with a median age of 64 [18-92] and 60% were female. The most prevalent APSO’s amongst the respondents were fear of progression or relapse (47%), fear of being immunocompromised (38%) and anxiety (34%). We assessed depression as a separate PRO from anxiety and found only 52% of those reporting anxiety also reported depression. Of all predictors examined, increasing age was significantly associated (p<0.0001) with a reduction in all but one APSO, fear of being immunocompromised (p=0.4).
CONCLUSIONS: These results suggest that the mosaic of APSO’s experienced by patients with lymphoma and CLL are diverse and extend solely beyond depression and anxiety. Our results also support the hypothesis that the prevalence of APSO’s are amplified younger patients. In the development and refinement of novel PROM’s, it will be imperative to incorporate a more diverse representation of APSO’s to truly reflect the experiences of this vulnerable population. Finally, the results suggest younger patients be assessed for APSO's to enable timely implementation of intervention measures.
METHODS: A cross-sectional survey was employed to gather patient reported-outcomes (PRO) from a global sample of patients with lymphoma or CLL in early 2024. Age, biological sex, relapse status, time since last treatment, and time since diagnosis were used as predictors to model the prevalence of 19 APSO’s utilizing nominal logistic regression.
RESULTS: The sample contained 6073 patient responses from 67 countries with a median age of 64 [18-92] and 60% were female. The most prevalent APSO’s amongst the respondents were fear of progression or relapse (47%), fear of being immunocompromised (38%) and anxiety (34%). We assessed depression as a separate PRO from anxiety and found only 52% of those reporting anxiety also reported depression. Of all predictors examined, increasing age was significantly associated (p<0.0001) with a reduction in all but one APSO, fear of being immunocompromised (p=0.4).
CONCLUSIONS: These results suggest that the mosaic of APSO’s experienced by patients with lymphoma and CLL are diverse and extend solely beyond depression and anxiety. Our results also support the hypothesis that the prevalence of APSO’s are amplified younger patients. In the development and refinement of novel PROM’s, it will be imperative to incorporate a more diverse representation of APSO’s to truly reflect the experiences of this vulnerable population. Finally, the results suggest younger patients be assessed for APSO's to enable timely implementation of intervention measures.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
P9
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Oncology